Second mitochondria-derived activator of caspase (Smac) is a mitochondrial protein released into the cytosol during apoptosis. Smac mimetics have recently been touted as a novel therapeutic to induce apoptosis in cancer cells. The ability of Smac mimetics to induce apoptosis in vitro has been shown to be dependent upon both XIAP neutralization and cancer cell autocrine tumor necrosis factor-a (TNF-a) production. In this study we provide new evidence for the utility of Smac mimetics in combination with conventional chemotherapy agents to exacerbate caspase activation and induce cancer cell death. Furthermore, we find that the combination effect is because of a multifaceted mechanism involving both inhibition of cell proliferation by the chemotherapy agents and an enhanced autocrine TNF-a feedback loop by the Smac mimetic/chemotherapy agent combination. Surprisingly, although genotoxic agents typically induce apoptosis through the mitochondrial intrinsic pathway, we show that this synergism is mediated through a TNF-a/RIP1-dependent pathway, leading to activation of the extrinsic apoptotic pathway. Finally, we report that autocrine TNF-a contributes to Smac mimetic-induced tumor regression as a single agent or in combination with chemotherapeutics in xenograft mouse models. Collectively, we provide mechanistic and applicable data to support translational studies in the use of a Smac mimetic/chemotherapy antineoplasm modality. Cancer is often the result of a complex paradigm of genetic and epigenetic alterations that results in dysregulated intracellular signaling pathways. The complex and heterogeneous mixture of cells that comprise the tumor mass often limit efficacy of conventional chemotherapy because of intrinsic or acquired drug resistance 1 or suppression of apoptosis.
Cancer is often the result of a complex paradigm of genetic and epigenetic alterations that results in dysregulated intracellular signaling pathways. The complex and heterogeneous mixture of cells that comprise the tumor mass often limit efficacy of conventional chemotherapy because of intrinsic or acquired drug resistance 1 or suppression of apoptosis. 2 Engagement of the apoptotic pathway by modulating pro-apoptotic factors has been proposed as an alternative strategy to trigger cancer cell death. 3, 4 At least two major signaling pathways exist in the induction of apoptosis. The intrinsic cell death pathway involves the permeabilization of mitochondria, resulting in release of proapoptotic factors such as cytochrome c and Smac/Diablo [5] [6] [7] into the cytosol, in which cytochrome c initiates apoptosome formation and activation of caspase-9 whereas second mitochondria-derived activator of caspase (Smac) relieves the inhibition of caspase by the inhibitors of apoptosis proteins (IAPs). The second apoptotic pathway or extrinsic pathway is initiated through the binding of tumor necrosis factor (TNF) superfamily proteins to their respective cell surface receptors, leading to the activation of caspase-8. 8 Activated caspase-8 and caspase-9 cleave and activate downstream caspases, including caspases 3 and 7, which then subsequently cleave their cellular substrates, resulting in apoptosis.
To develop a therapy targeted at abnormalities of apoptosis that have developed in cancer cells, mimetics of Smac were developed as small-molecule antagonists of IAP function to help initiate cancer cell death. Li et al. 9 first described the efficacy of a dimeric Smac mimetic (compound 3) to potentiate TRAIL and TNF-mediated cancer cell death. Later on, others have developed similar 'smac mimetic' approaches showing activity in various cancer lines. [10] [11] [12] [13] Similar to the endogenous Smac protein, Smac mimetics have been shown to compete with caspases for the binding of X-linked inhibitor of apoptosis protein (XIAP)and thereby release the inhibition on caspases imposed by XIAP. 9 In addition, Smac protein and Smac mimetics induce the proteasomal degradation of cellular inhibitors of apoptosis (cIAPs) [12] [13] [14] that promote the release of receptor interacting protein 1 (RIP1) from the TNFRI complex, leading to the formation of RIP1-dependent caspase-8 activation complex. 14, 15 In addition, loss of cIAP facilitates the stabilization of NIK, promoting IKK-a/IKK-a activation and NF-kB2 p100 processing to p52. 12, 13 The noncanonical nuclear factor k-light-chain-enhancer of activated B cell (NF-kB)-driven pathway upregulates specific target genes, including TNF-a that is required, in conjunction with neutralization of XIAP, for Smac mimetic-induced cell death. [12] [13] [14] [15] [16] As Smac mimetics enter clinical trials, it is critical to understand their mode of action as single agents or in combination with conventional chemotherapy to select appropriate patients or treatment regimens. With this intent, a series of cellular and pharmacological studies were used to address their clinical utility. In this study we show that the ability of a small, dimeric Smac mimetic, JP1400, to synergize with conventional cytotoxic agents is dependent on the production of TNF-a. Mechanistically, cell death is achieved through a multifaceted process including the inhibition of cellular proliferation and concomitant induction of TNF-a to provide a positive feedback loop, amplifying the TNF receptor-RIP1-dependent cell death pathway. Lastly, we provide novel evidence that in vivo treatment of xenograft tumors by Smac mimetics alone or in combination with chemotherapeutics is at least partially dependent on autocrine TNF-a.
Results
Biochemical activity of dimeric Smac mimetic, JP1400. A small-molecular-weight dimeric Smac mimetic, JP1400, was synthesized and its biochemical activity was compared with JP1010, also known as compound 3 by Li et al. 9 ( Figure 1a ). Both JP1010 and JP1400 induced degradation of cIAP1, whereas JP1400 showed superior degradation of cIAP2 over JP1010 (Figure 1b) . In a caspase de-repression assay, JP1400 was slightly better than JP1010 in relieving XIAP-mediated caspase-3 and -9 inhibitions (Figures 1c and d) . Given the improved cIAP2 activity of JP1400, it was selected for further studies.
Effects of JP1400/chemotherapy agent combinations in a variety of tumor cell lines. A screen of 50 non-small cell lung cancer cell (NSCLC) lines revealed that only 10-20% of NSCLC lines tested were sensitive to Smac mimetics as a single agent. 15 This low response rate could limit the usage of Smac mimetics as cancer therapeutics. We asked whether co-treatment with standard chemotherapy agents could render sensitivity to JP1400 in these Smac mimetic singleagent-resistant cells. In all, 10 different cancer cell lines, which are not sensitive to JP1400 single-agent treatment, were chosen for this purpose. The synergy between JP1400 and six chemotherapy agents, including gemcitabine, cisplatin, SN38, paclitaxel etoposide, was tested. IC 50 's were decreased by at least threefold in the presence of 100 nM JP1400 for at least two of the six drugs in the following five cell lines: A2058, MDA-MB435, HT-29, Miapaca-2 and Panc-1 ( Table 1) . The cell death response in A2058 cells are shown as examples in Supplementary Figure S1 . For future reference, these lines were labeled as 'sensitive' whereas the remaining five cell lines were labeled as 'resistant'.
Chemotherapy agents, but not JP1400, inhibit cell proliferation. To investigate the mechanism by which the chemotherapy agent/Smac mimetic combination induced cell death, cell viability and proliferation assays were performed. JP1400 slightly increased A2058 cell BrdU incorporation, whereas TNF-a had almost no effect on BrdU incorporation, suggesting that neither inhibits cell proliferation (Figure 2a ). The combination of TNF-a and JP1400 decreased BrdU incorporation. However, this effect was blocked by the addition of a pan caspase inhibitor, z-VAD, suggesting that the lower level of BrdU incorporation in these cells was likely because of apoptotic cell death and not antiproliferative effects. This is consistent with its effect on cell survival (Figure 2b ). On the other hand, gemcitabine alone was solely responsible for the antiproliferative effects of the chemotherapeutics/ JP1400 combination ( Figure 2a ). This observation is not unique to gemcitabine as etoposide, SN38, 5-FU, cisplatin and paclitaxel also blocked incorporation of BrdU in a dosedependent manner, irrespective of the presence or absence of z-VAD ( Figure 2c and Supplementary Figure S2 ).
Chemotherapeutics enhance JP1400-mediated caspase-3 cleavage. The apoptotic dependence of caspase activation for the chemotherapy agent/JP1400 combinations was examined in greater detail with western blots for caspase-3 cleavage. Dose titrations of gemcitabine or etoposide alone had no effect on the cleavage of pro-caspase-3 at 4 h ( Figure 2d ). Evidence of cleaved caspase-3 in combination with JP1400 revealed that this effect was entirely Smac mimetic dependent, as treatment of cells with JP1400 alone produced the same effect. As genotoxics generally require longer periods of time to initiate apoptosis, 17 we also examined caspase cleavage at 24 h. In combination with JP1400, gemcitabine and etoposide induced a dosedependent increase of caspase-3 cleavage that was substantially higher than treatment with JP1400 alone. This combination effect was also observed for cisplatin and SN38 (Supplementary Figure S3a) , and in another JP1400/ chemotherapy agent sensitive cell line, HT-29 cells (Supplementary Figures S3b and c) . With the exception of cisplatin at 100 mM, none of the chemodrugs alone induced significant caspase-3 activation, arguing against a direct mitochondrial role for the enhanced caspase activation by the chemodrugs. These data show that chemotherapy in combination with Smac mimetics can indeed enhance the Smac mimetic-induced apoptotic pathway to increase and accelerate cell death.
Chemotherapy/JP1400 synergism is dependent on autocrine TNF-a/RIP1 pathway. It has been previously shown that the molecular mechanism inherent in single-agent Smac mimetic sensitivity is dependent upon the presence of autocrine TNF-a. 12, 13, 15 Smac mimetics synergize with TNF-a to promote cell death through formation of a RIP1-dependent death-inducing complex. 14, 15 To investigate whether the chemotherapy agent/JP1400-dependent cell death was also because of autocrine TNF-a and a RIP1-dependent signaling pathway, cell viability experiments were performed in the presence of neutralizing anti-TNF-a antibody or in the background of RIP1 siRNAknockdown cells. Neutralizing TNF-a antibodies completely blocked the etoposide/JP1400-or SN38/JP1400-induced cell death and partially blocked gemcitabine/JP1400-or cisplatin/JP1400-induced cell death, suggesting that autocrine TNF-a is requisite for its cell killing abilities (Figure 3a ). This dependence on autocrine TNF-a was also observed for the combination effect in other cell lines (Supplementary Figure S4 , data not shown). In a similar manner, knockdown of RIP1 completely blocked the ability of all four chemotherapeutics to synergize with JP1400 and induce cell death (Figures 3b and c) . We next examined the effect of chemotherapy agents on RIP1-dependent caspase-8-activating complex formation. z-VAD was added to prevent the complex from falling apart. 15 After 24 h of treatment, JP1400 alone induced significant amount of RIP1/FADD/ caspase-8 complex formation (Figure 3d ). Gemcitabine treatment alone had no effect but it enhanced JP1400-induced complex formation, suggesting that gemcitabine synergizes with Smac mimetic to activate autocrine-TNF-a signaling.
Induction of TNF-a mRNA levels in response to JP1400 correlates with sensitivity to JP1400/chemotherapy agent combinations. It has been well established that Smac mimetic increases autocrine TNF-a production by inducing cIAP1/2 degradation, leading to the stabilization of NIK, and subsequently activation of noncanonical NF-kB pathway. 12, 13 To further solidify the necessity of TNF-a in chemotherapy/JP1400-induced cell death, the panel of cell lines used in Table 1 was tested for their ability to induce TNF-a mRNA expression in response to JP1400. After 4 h of treatment, cell lines that showed sensitivity to the chemotherapy agent/JP1400 combination showed three-to eightfold induction of TNF-a over untreated cells, whereas 'resistant' cells showed less than twofold induction (Figure 4a ). In contrast, mRNA levels of cIAP2, another NF-kB target gene, were induced fourfold or more in 9 of 10 cell lines tested (Figure 4b) .
Chemotherapy agents such as gemcitabine and cisplatin activate the ATM/ATR DNA-damage signaling pathways leading to ubiquitinylation of IKK-g/NEMO. This in turn releases the IKK-a/IKK-b complex and stimulates the canonical NF-kB pathway through degradation of IkB-a and subsequent nuclear translocation of p65 and Rel A proteins. 18 Indeed, A2058 cells showed decreased IkB-a levels and increased levels of NF-kB p65 in the nucleus after a 24-h treatment with gemcitabine (Figures 4c and d) . Consistently, gemcitabine was able to induce TNF-a mRNA levels by 27-fold, which was inhibited by pretreatment of cells with an IKK inhibitor (Figure 4e ). Similar results were obtained with the other chemotherapeutics (data not shown). To investigate whether chemotherapeutics could enhance Smac mimeticinduced TNF-a production, A2058 cells were treated with gemcitabine, etoposide, SN38 or cisplatin in the presence or absence of 100 nM JP1400. z-VAD was also added to prevent cell death. At 24 h, there was substantial induction of TNF-a by all chemotherapy agents alone, and an even greater synergistic induction was observed in the presence of JP1400. For instance, gemcitabine treatment led to a B60-fold induction of TNF-a mRNA, whereas co-treatment with JP1400 boosted that level to over 130-fold (Figure 4f ). cIAP2 expression was also induced in a similar manner, but to a lesser degree (Figure 4g ). z-VAD alone had no affect on TNF-a or cIAP2 expression (data not shown). To determine whether TNF-a protein levels correlated with the observed increase in TNF-a mRNA levels, a TNF-a ELISA was used to measure the secreted TNF-a levels in the conditioned cell culture medium. A2058 cells treated with JP1400 led to a twofold increase in TNF-a, whereas gemcitabine and the gemcitabine/JP1400 combination produced fourfold and sixfold higher levels of TNF-a, respectively (Supplementary Figure S5a ). On the other hand, A2058 cells have low endogenous cIAP2 protein levels and it is completely eliminated by JP1400 at 24 h regardless of whether gemcitabine is present (Supplementary Figure S5b) . ELISA ( Figure 5a ). Mice treated with JP1400 had significant levels of hTNF-a in the circulating plasma, suggesting that in a remarkably short amount of time, Smac mimetics penetrate tumor tissue and trigger the production of TNF-a. Similarly, when human TNF-a and cIAP2 mRNA levels were evaluated in the excised tumors of HCC461 xenograft mice, we observed an induction of 65-fold and 20-fold, respectively (Po0.0001; Figure 5b ). These results suggested that the in vivo tumor mimicked our observations in vitro. To provide conclusive evidence for whether TNF-a is required for Smac mimetic sensitivity of whole tumors, HCC461 xenograft mice were i.p. injected five times with 5 mg/kg of the soluble TNF receptor, etanercept. Mice were also i.v. injected at day 13 with 1 mg/kg JP1400. At day 22, saline or etanercept-treated mice had 41000 mg tumors whereas tumors in JP1400-treated mice were only approximately B200 mg (Figures 5c  and d) . Etanercept was only able to partially block JP1400-induced tumor cell killing with an average tumor weight of 431 mg at day 22 (P ¼ 0.007).
To ensure that the xenograft response was not unique to HCC461 tumors and that the observations could be translated to combination treatments, an additional cancer cell line, Miapaca-2, was also tested in a xenograft model. Gemcitabine had no effect on tumor cell growth whereas JP1400 alone limited tumor growth to 308 mg compared with 721 mg for saline control (P ¼ 0.004; Figures 6a and c) . This JP1400 single-agent effect was rather unexpected as JP1400 had minimal effect on Miapaca-2 cells in vitro (Supplementary Figure S6a) . The combination of gemcitabine and JP1400 resulted in a twofold decrease in tumor size compared with JP1400 alone (P ¼ 0.03), consistent with the in vitro combination effect (Supplementary Figure S6b) . Similar to that observed in HCC461 model, treatment of Miapaca-2 xenograft mice with etanercept partially blocked gemcitabine plus JP1400-induced tumor killing (P ¼ 0.002; Figures 6b and c) .
Discussion
It has been proven that the ability of Smac mimetic to bind XIAP, which releases its inhibition on caspases, as well as to induce cIAP degradation through proteasomal pathway, are both essential for its cell killing activities [12] [13] [14] [15] [16] (Figure 6d ). However, these anti-IAP functions cannot be used to predict the cell death response, because in all cell lines tested, regardless of their cell death response, Smac mimetic binds to XIAP and induces cIAP degradation (data not shown). There are two cellular events that result from cIAP degradation: (1) activation of the noncanonical NF-kB pathway and subsequently increased production of autocrine TNF-a and (2) release of RIP1 from the TNF-a receptor complex, leading to caspase-8 activation, which requires TNF-a receptor to be activated in the first place. Accumulating evidence suggest that whether or not Smac mimetic induces autocrine TNF-a production is the key factor in deciding the cell's fate upon Smac mimetic treatment. Depending on their response to Smac mimetics, cells can be grouped into three general classes: in class I cells, Smac mimetic induces autocrine TNF-a production and massive cell loss; 12, 13, 15 in class II cells, Smac mimetic still induces autocrine TNF-a production but this does not have a major effect on the cell population; and in class III cells, Smac mimetic has no effect on autocrine TNF-a production or on cell death. The ability of cells to produce TNF-a is necessary but not sufficient for Smac mimetic to induce cell death as a single agent. In class II cells, although autocrine-TNF-a production, RIP1-dependent caspase-8 complex formation and caspase-3 activation were induced by Smac mimetics, only marginal cell death was detected in these cells. As Smac mimetic/TNF-a signaling does not inhibit the cell cycle, it is critical that the cell death signal is strong enough to ensure massive cell death. Otherwise the surviving cells could continue to grow and compensate for the cell loss. Consistent with this notion, Smac mimetic does slightly enhance the cell proliferation rate, which was partially blocked in the presence of z-VAD (Figure 2) , suggesting that the increased cell growth may in part be a consequence of Smac mimetic-induced caspase activation and cell death. The mechanism behind this phenomenon warrants further investigation.
The extent of autocrine TNF-a induction and the relative levels of pro-apoptotic versus antiapoptotic proteins in different cells may distinguish class I versus class II cells. Use of Smac mimetics in combination with chemotherapy agents could convert at least some of the class II cells into sensitive cells. Enhanced Smac mimetic cell killing in combination with standard chemotherapeutics relies heavily on their ability to (1) inhibit cellular proliferation and (2) activate the canonical NF-kB pathway to exacerbate the production of TNF-a, thus enhancing the extrinsic cell death pathway (Figure 6d) . Surprisingly, the mitochondria-dependent, intrinsic apoptotic pathway initiated by genotoxics seems to be less important in this combination effect. Pretreatment of cells with either anti-TNF-a antibodies or RIP1 siRNA almost completely blocked Smac mimetic/ chemotherapy agent-induced cell death.
Both extrinsic and intrinsic determinants are critical for cancer cell survival and death. 19 Moreover, it has been suggested that all cancer cells have the capability to undergo apoptosis, but are prevented from doing so by signals from both neighboring cells and the tumor microenvironment. 20 The observation that chemotherapeutics can greatly enhance the level of TNF-a production in combination with Smac mimetics has many promising possibilities in itself. Strong induction of TNF-a localized to the tumor could mimic immunotherapy-based studies that show that high localized TNF-a reduces blood flow and causes tumor vasculature damage. 21 TNF-a may also modulate the immune response within the tumor by stimulating macrophage and NK cell activity. Synthesis of TNF-a by inflammatory cells in grade III invasive breast cancer patients correlated with fewer cases of recurrence and metastasis. 22 On the other hand, it is unclear how much TNF-a is required to overcome the survival threshold and induce apoptosis.
Different from Smac mimetic, which induces TNF-a production through activation of the noncanonical NF-kB pathway, 12, 13 chemotherapeutics can activate the canonical NF-kB pathway to enhance TNF-a production and death receptor-induced cell death. The ability of cells to produce TNF-a, but not cIAP2, in response to JP1400 correlates very well with its sensitivity to JP1400/chemotherapy combination. Understanding the mechanism of this differential response could provide a predictive biomarker for Smac mimetic therapy. We have found that for all cell lines tested, Smac mimetics clearly induce cIAP degradation and subsequent processing of NF-kB p100 (data not shown). Thus, the NF-kB nuclear translocation, the post-translational modifications of NF-kB including acetylation and phosphorylation, or epigenetic modifications and chromatin structure of the target gene promoter are more likely to determine the specific gene response in different cell lines. This question continues to provide an exciting area of future research in the use of Smac mimetics.
It is noteworthy that the Miapaca-2 cell line used in these studies is not sensitive to Smac mimetics alone in vitro, yet becomes sensitized to JP1400 in in vivo tumor xenograft models. Autocrine/paracrine TNF-a could be highly concentrated in the compact tumor microenvironment, which may lead to the enhanced Smac mimetic activity in vivo. Alternatively, the tumor microenvironment is complex and there might be other factors that contribute to Smac mimeticinduced cell death in tumors that are not recapitulated in cell culture systems. This finding highlights the potential that many more tumors might be sensitive to Smac mimetics as a single agent in vivo.
The observation that the mechanism of action of Smac mimetics alone or in combination with chemotherapy agents, in xenograft models, is at least partially dependent upon autocrine TNF-a is to the best of our knowledge the first documented report. Why the soluble TNF receptor, etanercept, was not able to fully block Smac mimetic or Smac mimetic/gemcitabine-induced tumor cell killing is not fully clear, but it may in fact be a result of the inability of etanercept to penetrate compact tumors. In addition, the compact tumor cell environment may lead to quick engagement of newly synthesized TNF-a with its receptor in an autocrine or paracrine manner, even before etanercept has had a chance to neutralize its action. Alternatively, etanercept is reported to preferentially bind soluble TNF-a over membrane-bound TNF-a. 23 Again, in a compact tumor microenvironment, cleavage of soluble TNF-a may not be necessary as membrane-bound TNF-a could directly bind and engage neighboring TNF receptors. On the other hand, it is not clear and also difficult to determine the pharmacokinetics of etanercept in the animal body and how this relates to its ability to counteract all the autocrine TNF-a action induced by Smac mimetic. Lastly, we cannot rule out the possibility that other factors may have a critical role in Smac mimetic-induced cell death in vivo. Further in vivo studies are warranted to fully understand the mechanistic and clinical effect of Smac mimetic-induced tumor regression and cell killing.
The above results suggest that combination therapy of conventional chemotherapeutics in conjugation with a smallmolecule Smac mimetic offers a promising strategy for the treatment of cancer. The efficacy of such treatments will be, in part, dependent upon intrinsic TNF-a levels or the ability of the Smac mimetic/chemotherapy combination to induce TNF-a, providing a potential predictive and clinically measurable biomarker.
Materials and Methods
Reagents. Pan-caspase inhibitor, z-VAD-FMK, was purchased from Biomol (Plymouth Meeting, PA, USA). Caspase substrates, Ac-DEVD-AMC, Ac-LEHD-AMC and IKK inhibitor IV, were obtained from Calbiochem (Gibbstown, NJ, USA). Cytochrome c, dATP, saline and SN38 were purchased from Sigma (St Louis, MO, USA) . Cisplatin was obtained from LC Laboratories (Woburn, MA, USA). Etoposide and 5-FU were obtained from LKT Laboratory (St Paul, MN, USA). Gemcitabine and paclitaxel were obtained from Polymed Therapeutics (Houston, TX, USA). ERK and NF-kB p65 antibodies were obtained from Cell Signaling (Danvers, MA, USA), and Histone H3 antibody was obtained from Abcam (Cambridge, MA, USA). All the other antibodies used in this study were previously described.
14 Etanercept was generously provided by Dr. Sherri Zhu.
Recombinant proteins. Recombinant Apaf-1 and pro-caspase-9 protein was kindly provided by Dr. Xiaodong Wang from UT Southwestern Medical Center at Dallas, TX, USA. GST-XIAP was generated as previously described. 24 Active caspase-3 was generated using baculovirus-expressing pro-caspase-3 25 that, when expressed in Sf21 insect cells for 424 h, autocleaved itself into active caspase-3. Active caspase-3 was purified using Ni-NTA agarose (Qiagen, Valencia, CA, USA) and Hitrap Q column (Amersham Biosciences, Piscataway, NJ, USA).
Caspase-3 and caspase-9 de-repression assays. For caspase-3 assays, a final volume of 30 ml was assembled on ice, including 3 ml of 10 Â caspase assay buffer (300 mM HEPES, pH 7.5, 1 M NaCl, 50% sucrose, 1% CHAPS, 200 mM b-mercaptoethanol and 20 mg/ml BSA), 25 0.5 nM GST-XIAP and 0.3 ml caspase-3 substrate (Ac-DEVD-AMC, 1 mM). The mixture was incubated at 301C for 10 min in the presence of 5 ml Smac mimetics and then supplemented with 5 ml of 0.25 nM caspase-3 to initiate the enzyme reaction. Fluorescent signal was measured using an automated spectrophotometer (Pherastar, BMG Labtech, Cary, NC, USA) at wavelengths of 350/460 nm (excitation/emission). For caspase-9 assays, 5 ml of Smac mimetics and 10 ml of a master mix was added each well, which included 50 nM Apaf-1, 200 nM cytochrome c, 10 mM dATP, 20 nM GST-XIAP, 100 Â caspase-9 substrate (Ac-LEHD-AMC, 1 mM) and buffer A (20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA and 1 mM DTT) with 0.2% CHAPS. Additional controls contained wells with no dATP or GST-XIAP. The plate was incubated at 301C for 10 min and then the reaction was initiated by the addition of 5 ml 2.5 mM pro-caspase-9 (20 nM final). The fluorescence reading was carried out as described for the caspase-3 assay.
Cell lines and cell viability assays. All cell lines except HCC461 were obtained from ATCC (Manassas, VA, USA). Cell lines A2058, BT474, G361, HT-29, Miapaca-2 and PANC-1 were cultured in DMEM (Hyclone, Waltham, MA, USA) supplemented with 10% FBS. HCC461, MDA-MB435, NCI-H226, NCI-H460 and PC-3 cells were cultured in RPMI-1640 (Hyclone) supplemented with 10% FBS. Cell viability assays were carried out as previously described.
14 BrdU cell proliferation assays. A2058 cells were seeded at 3000 cells/well in 96-well assay plates for 16-24 h. Cells were treated as indicated in the figure legends for another 24 h, followed by a 24-h labeling with BrdU reagent. BrdU incorporation was determined with a BrdU Cell Proliferation Assay Kit (Calbiochem) as per the manufacturer's instructions.
Preparation of cell lysates and caspase-8 immunoprecipitation. After the indicated treatment, cell pellet was collected and lysed in Buffer A (20 mM Hepes (pH 7.4), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA and 1 mM DTT) with 1% TX-100 and Complete protease inhibitor cocktail (Roche, Indianapolis, IN, USA) and then incubated on ice for 20 min. Lysates were then cleared by centrifugation at 14 000 r.p.m. for 30 min. The soluble fraction was kept and protein concentration determined by Bradford assay (Thermo Scientific, Waltham, MA, USA). The procedure for caspase-8 immunoprecipitation was described previously. 14 siRNA transfection. Luciferase and RIP1 siRNAs were synthesized at Dharmacon (Lafayette, CO, USA). Luciferase target sequences were as follows: 5 0 -AACGTACGCGGAATACTTCGA-3 0 ; RIP1 target sequence: 5 0 -CCACTA GTCTGACGGATAA-3 0 . siRNA or Dharma-Fect Duo (Dharmacon) were diluted in Opti-MEM medium (Invitrogen, Carlsbad, CA, USA) and transfected as suggested by Dharmacon.
ELISA analysis of plasma autocrine human TNF-a secretion. Blood samples were collected through jugular exsanguination. Plasma was separated by centrifugation of blood samples in lithium heparin plasma microtainer tubes (BD, San Jose, CA, USA) according to the manufacturer's protocol. Samples were kept at À801C until ready for use. ELISA was performed using a quantitative high sensitivity sandwich immunoassay from R&D Systems (Minneapolis, MN, USA) (Human TNF-a/TNFSF1A Quantikine HS ELISA, HSTA00D) as per the manufacturer's instructions.
RNA preparation, reverse transcription and real-time PCR. Total RNA was isolated using TRIzol Reagent (Invitrogen). RNA (1 mg) was reversed transcribed with Superscript II kit (Invitrogen) using the manufacturer's suggested guidelines. Real-time PCR was performed on an Applied Biosystems (Foster City, CA, USA) 7900HT real-time PCR machine with SYBR green technology. Primers for real-time PCR of cDNA were synthesized by IDT (Coralville, IA, USA) and are as follows: TNF-a forward (5 0 -GCAGGTCTACTTTGGGATCATTG-3 0 ), TNF-a reverse (5 0 -GCGTTTGGGAAGGTTGGA-3 0 ), cIAP2 forward (5 0 -CAAAGCATTGAAGTC TGCAGTTG-3 0 ), cIAP2 reverse (5 0 -GCAAGCATGGTTTCCTGGAT-3 0 ), cyclophilin forward (5 0 -TGCCATCGCCAAGGAGTAG-3 0 ) and cyclophilin reverse (5 0 -TG CACAGACGGTCACTCAAA-3 0 ). Real-time PCR cycling parameters were 501C for 2 min, 951C for 10 min, followed by 40 cycles of 951C for 15 s and 601C for 1 min each. TNF-a and cIAP2 data were normalized for expression with cyclophilin, and results were expressed as fold induction over untreated cells.
Preparation of nuclear and cytosol fractions. A2058 cells were plated in 10 cm dishes and treated as indicated. Cell pellets were resuspended in 400 ml of Buffer A with protease inhibitor. After 15 min of incubation on ice, 25 ml of 10% NP-40 was added and the samples were vortexed vigorously. After centrifugation at 3000 Â g for 10 min at 41C, the supernatant was saved as cytosol fraction. The pellet was washed once with Buffer A and was further resuspended in 75 ml of Buffer B (Buffer A with 5% glycerol and 400 mM NaCl). Samples were incubated on ice for 30 min and centrifuged at 10 000 Â g for 5 min at 41C. The supernatant was saved as the nuclear faction.
In Vivo HCC461 and Miapaca-2 xenograft models. Female athymic nude-Foxnlnu (Harlan) mice, 5 to 6 weeks old, were injected subcutaneously with 1 Â 10 7 HCC461 or Miapaca-2 cells. After 6 to 7 days, when tumors had reached B200 mm 3 , mice were randomized into treatment groups of eight mice per group for the tumor growth experiments. As for the TNF-a ELISA and tumor RNA extraction experiment, animals were randomized into treatment groups of five mice per group when tumors had reached B500 mm 3 . JP1400 or vehicle (saline) was i.v. administered in a total volume of 200 ml. Gemcitabine, etanercept or vehicle (saline) was i.p. injected in a total volume of 200 ml. The dose used for each drug is shown in the figure legend. Tumors were measured twice a week with vernier calipers. Tumor volumes were calculated according to (length Â width 2 )/2. All animal experiments were performed according to the OLAW and USDA guidelines and under an approved IACUC use protocol.
Statistical analysis. Results were analyzed for statistical significance using the unpaired two-tailed Student's t-test (Graphpad, La Jolla, CA, USA).
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